Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1

Affiliations

• ¹ Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
• ² Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
• ³ Department of Infectious Diseases and Applied Immunology, IMSUT Hospital, Institute of Medical Science, University of Tokyo, Tokyo, Japan; Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
• ⁴ Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan; Division of Infectious Diseases, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
• ⁵ Department of Infectious Diseases and Applied Immunology, IMSUT Hospital, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
• ⁶ Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, University of Tokyo, Kashiwa, Chiba, Japan.
• ⁷ Clinic of Nihon Sumo Kyokai, Tokyo, Japan.
• ⁸ Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan; Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA; The University of Tokyo Pandemic Preparedness, Infection and Advanced Research Center, Tokyo, Japan. Electronic address: yoshihiro.kawaoka@wisc.edu.